The Cell-Based Assay Market Will Reach $6.9bn In 2020, A New Study Predicts

06 September 2018
Pharma

A new report by visiongain forecasts the world cell-based assay market will reach $6.9bn in 2020. That revenue prediction and others appear in Cell-Based Assays World Industry and Market Prospects 2016-2026: Products, Services, Drug Discovery, ADME and Basic Research, published in May 2016. Visiongain is a business information publisher and consultancy in London, UK.

The analysis predicts the global cell-based assays market will continue to grow at a CAGR of 12.4% from 2015-2020, driven by the products and drug discovery segments. In 2015, drug discovery will be the leading market application of cell-based assays with revenues of $2.5bn. Drug discovery will remain as the leading market application throughout the coming decade.
Demand for the market will be fuelled by requirements within the pharmaceutical industry to reduce the failure rates of clinical trials dedicated to finding new therapeutic compounds. Such trials are limited by the effectiveness of the assays available for investigation of new drugs. This is where the latest cell-based assay technology, covered in this report, will excel over the next 10 years.
Robert King, a pharmaceutical and healthcare industry analyst in visiongain, said:
“New technological advances in the cell-based assay industry will see it go from strength-to-strength over the next decade. The advantages they hold over traditional animal based methods in drug development and diagnostics have led to growing demand. Failure rates in clinical trials have been high in the past two decades, with many (just under a third) resulting from issues with toxicity and safety. Given this, cell-based assays have become the preferred tool for screening potential drug compounds and toxicity screening. Organisations require effective early models for predicting toxicity, in order to reduce the risk of late-stage failure, which can cost companies millions of dollars. This is a huge driver for the cell-based assays market.
The last decade has seen the rapid increase in the application of cell-based assays among the pharmaceutical and academic industries and, according to visiongain’s forecasts, this rapid growth is set to continue over the next ten years. Advanced Cell-Based Assays, which utilise 3D cellular environments, are the latest development within the industry. These latest developments will create new opportunities in applications, services and products”.
This report investigates commercial trends and revenues of the cell-based assay market from 2016 to 2026, as well as including data from 2015. This report discusses sales potentials of:

• The market divided into two key ways:
o By services and products
o By application
 Drug discovery
 ADME (absorption, distribution, metabolism and excretion)
 Basic research

• 11 leading individual national markets including:
o US
o Japan
o EU5 (Germany, France, UK, Italy and Spain)
o BRIC (Brazil, Russia, India and China)

This report qualitatively discusses:

• 11 leading cell-based assay product suppliers including:
o ThermoFisher Scientific
o DiscoveRx
o GE Healthcare
o Promega

• 9 leading cell-based assay service providers including:
o Fluofarma
o CYTOO
o Cell Assay Innovations (CAI)
o ProQinase

• The future trends and outlooks in the cell-based assay market including:
o Organoid technology
o 3D bioprinting
o Microfluidics
o Label-free systems
o Induced pluripotent stem cells (IPSCs)

• Strengths, weaknesses, opportunities and threats of the global cell-based assay market

Recent News

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

Read

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

Read

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

Read

Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2021-2031

Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.

12 July 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever